医学
慢性阻塞性肺病
睾酮(贴片)
体质指数
内科学
置信区间
人口
肺病
环境卫生
作者
Ai-Hsi Hsu,Din-Yaung Chen,Jen‐Jyh Lee
标识
DOI:10.6440/tzucmj.200604.0113
摘要
Objective: To characterize the serum testosterone distribution in a population with chronic obstructive pulmonary disease (COPD) and discuss the potential impacts of anabolic steroids in weight-depleted COPD patients. Materials and Methods: Between July and September 2005, forty male participants aged over 50 years who COPD were enrolled and divided into 4 groups of increasing severity (I~IV). The grouping method was based on the classification of COPD severity suggested by the Global Initiative for Chronic Obstructive Lung Disease (GOLD). The control group included 173 age-matched healthy males who were being followed-up in the urology clinics of Tzu Chi General Hospital and was labeled group V. One-way ANOVA and t-test were used to test for differences in several variables including age, serum testosterone level, peak flow meter values (PEF), and body mass index (BMI) among these 5 groups. Results: In this study, the prevalences of hypogonadism (defined as total serum testosterone of <3ng/mL) in healthy aging males and COPD patients were 25% and 33%, respectively. The testosterone level in group Ⅳ (with the most severe COPD) was lower than those of the other groups. After removing group Ⅳ, the 95% confidence interval of serum testosterone level was between 4.136 and 4.687 ng/mL. In addition, group Ⅳ was independently isolated, and the t-test was used to compare differences between group Ⅳ and the other 4 groups as a whole. The results confirmed that the serum testosterone level, PEF, and body mass index in group Ⅳ were significantly lower than those of the other 4 groups. Conclusions: Testosterone levels showed no significant differences among group Ⅰ, Ⅱ, Ⅲ, and Ⅴ in this study; however, patients in group Ⅳ might have decreased maintenance of serum testosterone levels, and this might be considered to contribute to the skeletal muscle wasting in some COPD patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI